AIMS Service Category

Early-stage Development Guide for Advanced Biotherapeutics

Translate basic research outputs into CMC, nonclinical, and clinical entry plans.

AIMS reviews manufacturability, quality attributes, analytical methods, nonclinical evaluation feasibility, cost, and timeline to determine development readiness and priority tasks for advanced biotherapeutic candidates.

CMC Plan CQA Analytical Method Plan Nonclinical Plan FIH Readiness
Why it matters

Basic research success is not the same as development readiness.
For advanced biotherapeutics, product characteristics and CMC/quality foundations determine nonclinical study interpretation and clinical entry feasibility.

Recommended for clients with promising basic research results
that need a development entry plan.

This category supports clients with cell/gene therapy, EV, organoid, or other advanced biotherapeutic technologies that need to move from research results to CMC, nonclinical, and clinical entry planning.

AS IS
  • Basic research results exist, but development entry feasibility is unclear.
  • Manufacturing process, quality attributes, potency assay, and CQA are not defined.
  • Modality-specific nonclinical evaluation items are unclear.
  • External provider use, cost, timeline, and milestones are not concrete.
TO BE
  • Development feasibility and early risks are organized from CMC, nonclinical, and clinical entry perspectives.
  • Initial CMC and quality strategy required for nonclinical and clinical entry is established.
  • Necessary evaluation items such as biodistribution, toxicity, tumorigenicity, and immunogenicity are defined.
  • CRO, analytical lab, and manufacturing provider plans with cost and timeline guidance are prepared.

How early research is converted into development entry

AIMS determines whether research-stage technology can enter development and what must be resolved first, combining CMC, quality, nonclinical, regulatory, and external provider perspectives.

Development potential

Assess whether basic research evidence can support transition to development.

01

CMC and quality

Define initial manufacturing, quality attributes, CQA, potency, and analytical strategy.

02

Nonclinical entry plan

Define modality-specific nonclinical evaluation, providers, cost, and timeline.

03

Service modules

The modules are applied individually or in combination according to the current state of the candidate technology.

Development Potential Assessment Based on Basic Research Results

This service distinguishes development-enabling elements from issues that must be resolved first by reviewing efficacy, mechanism, candidate characteristics, and early quality/nonclinical risks.

Core question
Can this basic research output enter the actual development stage?
Why this service matters
Promising research results can still lead to repeated development and delay if manufacturability, quality attributes, analytical methods, safety evaluation feasibility, and regulatory acceptability are not reviewed early.

What can go wrong
if this is not addressed?

01

Development judged only by efficacy

CMC and nonclinical feasibility may be insufficiently assessed.

02

Mechanism not linked to clinical need

Development rationale and entry indication may be weak.

03

Manufacturing/quality not reviewed

Repeated work may occur during CMC development.

Multidisciplinary participation

The radial chart shows participating expertise only. RACI roles and contributions are shown in the table.

Development Potential Assessment Based on Basic Research Results multidisciplinary participation graph
Accountable Responsible Consulted Informed

Role by expertise

RoleExpertiseContribution
AAdvanced Therapy Strategy

Sets development transition judgment and early decision direction.

RNonclinical Development

Reviews efficacy evidence, models, biodistribution, toxicity, tumorigenicity, and immunogenicity feasibility.

RCMC / Quality

Reviews process, quality attributes, potency, characterization, and release test needs.

CClinical Development

Advises whether research results can link to clinical need and entry indication.

CRegulatory Strategy

Identifies early data and gaps likely to be requested before clinical entry.

CExternal Provider Network

Advises availability of manufacturing, analytical, and nonclinical providers.

When clients need this service

Client situationAIMS value
An early cell/gene therapy, EV, organoid, or other candidate needs development feasibility assessment.Evaluates development entry potential and early risks.
Basic efficacy exists but CMC/nonclinical readiness is unclear.Identifies gaps to resolve before development transition.
Investment or collaboration discussions require development feasibility explanation.Structures a development entry rationale for external stakeholders.

Workflow

01

Review candidate and research data

Review MoA, modality, efficacy, manufacturing status, and data package.

02

Connect to clinical need

Assess how the technology may address medical unmet needs.

03

Check early CMC/quality risks

Review process, materials, attributes, analytical methods, and potency feasibility.

04

Review nonclinical feasibility

Assess efficacy, biodistribution, toxicity, tumorigenicity, immunogenicity items.

05

Summarize feasibility and risks

Separate development-enabling elements from prerequisites.

06

Recommend next stage

Connect to early CMC strategy, nonclinical plan, and cost/timeline estimation.

Representative deliverables

Development potential assessment report

Assessment of research results and development transition feasibility.

Early development risk summary

Key CMC, nonclinical, and clinical-entry risks and prerequisites.

Development entry recommendation

Priorities and direction required for CMC and nonclinical strategy.

Follow-on service linkage memo

Recommended next tasks leading to CMC plan, nonclinical guide, and roadmap.

Relevant standards by service

AIMS defines the standards and guideline anchors that should be considered for each service, rather than treating them as optional references.

ServiceRelevant standardsHow they are applied
Development Potential AssessmentICH S6(R1), S12, M3(R2), Q5 seriesReview early nonclinical and quality considerations for biotechnology-derived products and gene therapy products.
Early CMC and Quality StrategyICH Q5A/Q5B/Q5C/Q5D/Q5E, Q2(R2), Q14Define quality, characterization, stability, comparability, analytical procedure, and validation strategy.
Nonclinical Evaluation and Clinical Entry GuideICH M3(R2), S6(R1), S12, S7A/S7B, M10Define modality-specific nonclinical, safety pharmacology, biodistribution, TK/PK, and bioanalysis evidence for clinical entry.

Core terms

CMC

Chemistry, Manufacturing and Controls, including process, quality, analytical, and control strategy.

CQA

Critical Quality Attribute that should be controlled because it may affect safety, efficacy, or quality.

Potency assay

An assay measuring biological activity linked to the product’s mechanism of action.

FIH readiness

Readiness of evidence, materials, and documentation to support first-in-human entry.